Zencurix "Breast Cancer Prognostic Test Jinswell BCT, First Direct Prescription at General Hospitals"

[Asia Economy Reporter Hyunseok Yoo] GenCurix announced on the 2nd that it has completed the domestic comprehensive hospital code registration (coding) for the breast cancer prognosis diagnostic test ‘Jinswell BCT’ and that sales through direct prescriptions have officially begun. Additional product code registrations are currently underway at numerous general hospitals and university hospitals, and as the number of hospitals completing coding increases, sales are expected to rise significantly in sequence.

Jinswell BCT is the first and only breast cancer prognosis diagnostic test in Asia to obtain official sales approval from national authorities. Following formal approval from the Ministry of Food and Drug Safety, it was approved as an innovative medical technology last year. This has finally made it possible to directly prescribe the test to patients through code registration at general hospitals.

Low-risk patients with a low risk of recurrence after breast cancer surgery do not require chemotherapy, which involves painful side effects. However, existing pathological examination methods have low accuracy in prognosis prediction, failing to properly identify low-risk patients, resulting in overtreatment where patients who do not need chemotherapy still receive it. Jinswell BCT is a test developed by GenCurix using proprietary biomarker technology and algorithms to accurately predict the probability of recurrence within 10 years and assist in determining the chemotherapy direction for breast cancer patients.

Currently, in Korea, a few foreign breast cancer prognosis diagnostic tests, such as those from the US company E, are sold at high prices exceeding 4 million KRW per test without domestic clinical results or approval from the Ministry of Food and Drug Safety. Since breast cancer varies significantly among races, the medical community has repeatedly pointed out the low reliability of Western breast cancer prognosis diagnostic tests that have not succeeded in Asian clinical trials.

Jinswell BCT has succeeded in multiple clinical trials targeting domestic patients and secured reliability through official approval based on these results. In addition to the strength of test accuracy, it is also evaluated to have outstanding price competitiveness. Unlike competing products that take three weeks to produce results, Jinswell BCT can provide results within a week, allowing for rapid determination of appropriate treatment methods, which is another important advantage.

Based on this, the company plans to rapidly expand its market share by replacing unauthorized foreign tests. Hospitals that hesitated to introduce unauthorized foreign tests are expected to adopt the officially approved Jinswell BCT, which will lead to an increase in market share and a significant rise in the total number of breast cancer prognosis diagnostic tests conducted domestically.

Jang Sang-rae, CEO of GenCurix, said, “The purpose of establishing the company 10 years ago was to minimize unnecessary chemotherapy pain and reduce economic burdens for patients by having all domestic general hospitals performing breast cancer surgery adopt the Jinswell BCT test.” He added, “In addition to hospitals where code registration has been completed, many other hospitals are in the process of code registration, so the number of hospitals able to directly prescribe the test will increase significantly.”

He continued, “With the comprehensive hospital code registration of Jinswell BCT this time, it is expected that breast cancer prognosis diagnostic tests will become widespread in Korea as in advanced countries,” and “We will do our best to establish ourselves as the unrivaled number one breast cancer prognosis diagnostic test not only in Korea but also in Asia.”

This content was produced with the assistance of AI translation services.